Literature DB >> 12124429

Caspase cleavage of members of the amyloid precursor family of proteins.

Veronica Galvan1, Sylvia Chen, Daniel Lu, Anna Logvinova, Paul Goldsmith, Edward H Koo, Dale E Bredesen.   

Abstract

The synapse loss and neuronal cell death characteristic of Alzheimer's disease (AD) are believed to result in large part from the neurotoxic effects of beta-amyloid peptide (Abeta), a 40-42 amino acid peptide(s) derived proteolytically from beta-amyloid precursor protein (APP). However, APP is also cleaved intracellularly to generate a second cytotoxic peptide, C31, and this cleavage event occurs in vivo as well as in vitro and preferentially in the brains of AD patients (Lu et al. 2000). Here we show that APPC31 is toxic to neurons in primary culture, and that like APP, the APP family members APLP1 and possibly APLP2 are cleaved by caspases at their C-termini. The carboxy-terminal peptide derived from caspase cleavage of APLP1 shows a degree of neurotoxicity comparable to APPC31. Our results suggest that even though APLP1 and APLP2 cannot generate Abeta, they may potentially contribute to the pathology of AD by generating peptide fragments whose toxicity is comparable to that of APPC31.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124429     DOI: 10.1046/j.1471-4159.2002.00970.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  41 in total

1.  Perspectives on herpes-APP interactions.

Authors:  E L Bearer
Journal:  Aging Cell       Date:  2004-04       Impact factor: 9.304

2.  MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma.

Authors:  Saif Zaman; Boris I Chobrutskiy; George Blanck
Journal:  Cell Cycle       Date:  2018-11-18       Impact factor: 4.534

3.  Amyloid, tau, and cell death in Alzheimer's disease.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-08-26

4.  A pilot proteomic study of amyloid precursor interactors in Alzheimer's disease.

Authors:  Barbara A Cottrell; Veronica Galvan; Surita Banwait; Olivia Gorostiza; Christian R Lombardo; Tristan Williams; Birgit Schilling; Alyson Peel; Bradford Gibson; Edward H Koo; Christopher D Link; Dale E Bredesen
Journal:  Ann Neurol       Date:  2005-08       Impact factor: 10.422

5.  Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624).

Authors:  G M Shaked; M P Kummer; D C Lu; V Galvan; D E Bredesen; E H Koo
Journal:  FASEB J       Date:  2006-04-24       Impact factor: 5.191

6.  C-terminal cleavage of the amyloid-beta protein precursor at Asp664: a switch associated with Alzheimer's disease.

Authors:  Surita Banwait; Veronica Galvan; Junli Zhang; Olivia F Gorostiza; Marina Ataie; Wei Huang; Danielle Crippen; Edward H Koo; Dale E Bredesen
Journal:  J Alzheimers Dis       Date:  2008-02       Impact factor: 4.472

7.  Interaction of ASK1 and the beta-amyloid precursor protein in a stress-signaling complex.

Authors:  Veronica Galvan; Surita Banwait; Patricia Spilman; Olivia F Gorostiza; Alyson Peel; Marina Ataie; Danielle Crippen; Wei Huang; Gurleen Sidhu; Hidenori Ichijo; Dale E Bredesen
Journal:  Neurobiol Dis       Date:  2007-07-03       Impact factor: 5.996

8.  Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664.

Authors:  Thuy-Vi V Nguyen; Veronica Galvan; Wei Huang; Surita Banwait; Huidong Tang; Junli Zhang; Dale E Bredesen
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

9.  Netrin-1 interacts with amyloid precursor protein and regulates amyloid-beta production.

Authors:  F C Lourenço; V Galvan; J Fombonne; V Corset; F Llambi; U Müller; D E Bredesen; P Mehlen
Journal:  Cell Death Differ       Date:  2009-01-16       Impact factor: 15.828

10.  Increased APLP1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates.

Authors:  Tomás R Guilarte; Neal C Burton; Tatyana Verina; Vinaykumar V Prabhu; Kevin G Becker; Tore Syversen; Jay S Schneider
Journal:  J Neurochem       Date:  2008-02-13       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.